![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
High Medication Adherence in HCV-Infected Patients Taking a Triple-DAA Regimen for 12 Weeks
|
|
|
Reported by Jules Levin
AASLD 2013 Nov 1-4 Wash DC
Marc Bourliere1, Fred Poordad2, Bernard Vrijens3, Daniel Cohen4, Wangang Xie4, Marti n King4, Thomas Podsadecki4
1Hôpital Saint Joseph, Marseille, France; 2The Texas Liver Insti tute, University of Texas Health Science Center, San Antonio, Texas, United States; 3MWV Healthcare, Richmond, Virginia, United States; 4AbbVie Inc., North Chicago, Illinois, United States
![AASLD1.gif](../images/110613/110613-2/AASLD1.gif)
![AASLD2.gif](../images/110613/110613-2/AASLD2.gif)
![AASLD3.gif](../images/110613/110613-2/AASLD3.gif)
![AASLD4.gif](../images/110613/110613-2/AASLD4.gif)
![AASLD5.gif](../images/110613/110613-2/AASLD5.gif)
![AASLD6.gif](../images/110613/110613-2/AASLD6.gif)
![AASLD7.gif](../images/110613/110613-2/AASLD7.gif)
![AASLD8.gif](../images/110613/110613-2/AASLD8.gif)
![AASLD9.gif](../images/110613/110613-2/AASLD9.gif)
![AASLD10.gif](../images/110613/110613-2/AASLD10.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|